Bictegravir is a second-generation integrase inhibitor originally developed for HIV-1 infection. It is structurally related to dolutegravir and has been investigated as part of a single-tablet regimen with tenofovir alafenamide and emtricitabine.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1644158-10-0
Methyl 5-((2,4-difluorobenzyl)carbamoyl)-1-(2,2-dimethoxyethyl)-3-methoxy-4-oxo-1,4-dihydropyridine-2-carboxylate
research compound
2-[(1R,5S,6S)-3-ethyl-6-(nitromethyl)-6-bicyclo[3.2.0]hept-3-enyl]acetic acid;phenylmethanamine
pharmaceutical intermediate
BENZYL TRANS-4-ETHOXY-2-(4-METHOXYCARBONYLPHENYL)PIPERIDINE-1-CARBOXYLATE
pharmaceutical intermediate
Methyl 4-((2S,4S)-4-ethoxypiperidin-2-yl)benzoate
pharmaceutical intermediate
5-Bromo-2-hydroxy-4-methylpyridine
pharmaceutical intermediate
2-(4-Hydroxy-6-methylnicotinamido)-2-(4-hydroxyphenyl)acetic acid
pharmaceutical intermediate
methyl 1-(2,2-dimethoxyethyl)-3-methoxy-4-oxo-5-[(2,4,6-trifluorophenyl)methylcarbamoyl]pyridine-2-carboxylate
RAIISLLLTMSJCR-UHFFFAOYSA-N
COC1=C(N(C=C(C1=O)C(=O)NCC2=C(C=C(C=C2F)F)F)CC(OC)OC)C(=O)OC
—